HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lombard, C. W. Articles by Bussadori, C. M. Search for Related Content PubMed PubMed Citation Articles by Lombard, C. W. Articles by Bussadori, C. M.

Clinical Efficacy of Pimobendan Versus Benazepril for the Treatment of Acquired Atrioventricular Valvular Disease in Dogs

From the Klinik für kleine Haustiere, Universität Bern (Lombard), Länggassstrasse 128, 3012, Bern, Switzerland; the Clinica Gran Sasso(Bussadori), Via Donatello 26, 20131 Milano, Italy; Boehringer Ingelheim Vetmedica GmbH (Jöns), Preclinical and Clinical Development, 55216 Ingelheim/Rhein, Germany.

Address all correspondence to Dr. Jöns.

Seventy-six dogs with clinical acquired atrioventricular valvular disease were evaluated to determine the efficacy of pimobendan (n=41) versus benazepril hydrochloride (n=35) in a randomized, positive-controlled, multicenter study. The study was divided into 56-day and long-term evaluation periods. In a subgroup of dogs with concurrent furosemide treatment (pimobendan [n=31], benazepril [n=25]), the Heart Insufficiency Score improved in favor of pimobendan (P=0.0011), equating to a superior overall efficacy rating (P<0.0001) at day 56. Long-term median survival (i.e., death or treatment failure) for dogs receiving pimobendan was 415 days versus 128 days for dogs not on pimobendan (P=0.0022).